World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Laura L. Johnson net worth and biography

Laura Johnson Biography and Net Worth

Director of Kintara Therapeutics

Laura Johnson has served as a director since June 26, 2020. Ms. Johnson currently serves as the President and Chief Executive Officer of Next Generation Clinical Research, a contract research organization that Ms. Johnson founded in 1999. Additionally, Ms. Johnson is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a development biotechnology company that she founded in 2016. Ms. Johnson is also a founder and former member of the board of directors of SB Bancorp, Inc., a financial holding company, and Settlers Bank, Inc., a Wisconsin chartered business bank. In addition, Ms. Johnson has served as a member of the board of directors of La Jolla Pharmaceutical Company (Nasdaq: LJPC), a biopharmaceutical company, since 2013, Odonate Therapeutics (Nasdaq: ODT), a biopharmaceutical company, since 2018, Harmony Hill Farm Sanctuary since 2019 and Agrace HospiceCare from 2013 to 2016. In 2008 and 2010, she was honored as a biotechnology entrepreneur by the national organization, Women in Bio, and in 2008 received the Rising Star Award by the Wisconsin Biotech and Medical Device Association. Most recently, she was the recipient of the Wisconsin Biohealth Business Award at the BioForward Annual Biohealth Summit in October 2019. Ms. Johnson holds a nursing degree from The University of the State of New York-Albany.

What is Laura L. Johnson's net worth?: The estimated net worth of Laura L. Johnson is at least $5,228.38 as of August 21st, 2023. Ms. Johnson owns 33,091 shares of Kintara Therapeutics stock worth more than $5,228 as of April 25th. This net worth evaluation does not reflect any other assets that Ms. Johnson may own. Learn More about Laura L. Johnson's net worth.
How do I contact Laura L. Johnson?: The corporate mailing address for Ms. Johnson and other Kintara Therapeutics executives is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. Kintara Therapeutics can also be reached via phone at (858) 350-4364 and via email at [email protected]. Learn More on Laura L. Johnson's contact information.
Has Laura L. Johnson been buying or selling shares of Kintara Therapeutics?: Laura L. Johnson has not been actively trading shares of Kintara Therapeutics over the course of the past ninety days. Most recently, on Monday, November 22nd, Laura L. Johnson bought 3,000 shares of Kintara Therapeutics stock. The stock was acquired at an average cost of $0.74 per share, with a total value of $2,220.00. Learn More on Laura L. Johnson's trading history.
Who are Kintara Therapeutics' active insiders?: Kintara Therapeutics' insider roster includes Laura Johnson (Director), Anthony Praill (CFO), and Saiid Zarrabian (Insider). Learn More on Kintara Therapeutics' active insiders.

Laura L. Johnson Insider Trading History at Kintara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/22/2021	Buy	3,000	$0.74	$2,220.00

Laura L. Johnson Buying and Selling Activity at Kintara Therapeutics

Kintara Therapeutics Company Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Today's Range

Now: $0.16

$0.13

$0.16

50 Day Range

MA: $0.11

$0.08

$0.16

2 Week Range

Now: $0.16

$0.08

$5.98

Volume

11,062,931 shs

Average Volume

13,237,778 shs

Market Capitalization

$6.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57